Boehringer and BioMed X collaborate on epigenetic regulators of COPD

Subscribe via: RSS

Big pharma, Partnering

Boehringer and BioMed X collaborate on epigenetic regulators of COPD

Posted on 06 January 2015

Tags: big pharma, Boehringer Ingelheim, partnering

BioMed X have entered into a collaboration agreement with Boehringer Ingelheim to establish a research group focusing on the identification of novel therapeutic concepts for treating patients with chronic obstructive pulmonary disease (COPD).

Searching for more deal information? Current Partnering offers the following options:

CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities

BioMed X will be responsible for recruitment of the new research group, the operation of the innovation center facility, providing entrepreneurial education and enabling access to the Heidelberg scientific community and research facilities.

For further deal information visit Current Agreements (subscription required)

View: Top pharmaceutical companies

View: Top biotech companies

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends